Changeflow GovPing Pharma & Drug Safety NURIX BTK Degrading Compounds, 36 Claims, Apr 14
Routine Rule Added Final

NURIX BTK Degrading Compounds, 36 Claims, Apr 14

Favicon for changeflow.com USPTO Patent Grants - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO granted Patent US12600732B2 to NURIX THERAPEUTICS, INC. on April 14, 2026. The patent covers 36 claims for bifunctional compounds that degrade BTK via the ubiquitin proteolytic pathway, along with pharmaceutical compositions and methods of treatment for various diseases, conditions, or disorders.

What changed

USPTO granted Patent US12600732B2 to NURIX THERAPEUTICS, INC. covering 36 claims for bifunctional compounds designed to degrade BTK (Bruton's tyrosine kinase) through the ubiquitin proteolytic pathway. The patent also covers pharmaceutical compositions comprising these compounds and methods of using them to treat various diseases, conditions, or disorders.

For pharmaceutical and biotechnology companies, this patent establishes NURIX's intellectual property rights in the BTK degradation space via PROTAC technology. Competitors developing similar bifunctional compounds targeting BTK through ubiquitin-mediated degradation should assess freedom-to-operate implications and potential licensing needs.

What to do next

  1. Monitor patent portfolio for competitive analysis
  2. Review patent claims for freedom-to-operate assessment

Archived snapshot

Apr 15, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway

Grant US12600732B2 Kind: B2 Apr 14, 2026

Assignee

NURIX THERAPEUTICS, INC.

Inventors

Aileen Kelly, Arthur T. Sands

Abstract

This disclosure relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway. The description also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

CPC Classifications

C07D 487/04 A61P 35/00 A61P 19/00 A61P 37/00 A61K 31/40 A61K 31/403 A61K 31/4035

Filing Date

2023-03-10

Application No.

18120341

Claims

36

View original document →

Named provisions

Bifunctional compounds for degrading BTK Pharmaceutical compositions Methods of treatment

Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12600732B2

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent granting BTK inhibitor research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!